https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2013-11-25 13:54:072016-11-25 13:59:422013 ASH: Phase I/II Open-label study of AT7519 alone and in combo with bortezomib in pts with MM
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2011-11-25 13:59:542016-11-25 14:05:412011 EORTC: Phase 1 Study of AT7519M Short Infusion Twice Weekly
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2009-11-25 14:01:412016-11-25 14:09:472009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase 1 Study
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2008-08-25 14:10:082016-11-25 14:10:362008_A Dose Escalation, PK and PD Study of AT7519 in Patients with Refractory Solid Tumors
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2008-05-25 14:10:412016-11-25 14:11:072008 ASH_AT7519 is Active in CLL Patient Samples Independent of Stage
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2007-07-25 14:11:472016-11-25 14:12:322007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Samples
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2007-04-25 14:12:422016-11-25 14:13:062007_Comparison of AT7519 in Solid Tumor and Hematological Cell Lines
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok